Gastrointestinal stromal tumors presenting as pel vie masses: Report of two cases

We present two cases of gastrointestinal stromal tumors (GISTs) that presented as pelvic masses. These tumors can present diagnostic problems and they may be difficult to discover preoperatively. GISTs are neoplasms that can be diagnosed utilizing immunohistochemistry, especially detecting CD117 (c-kit) reactivity along with associated histological features. GISTs, should be considered in the differential diagnosis of ovarian tumors especially when imaging studies and rectovaginal examination findings are inconclusive and vague. Histologic diagnosis of these tumors are important considering the efficacy of tyrosine kinase inhibitor therapy after surgery in such cases.

GIST; Pelvic mass; CD 117; c-kit; lmatinib mesylate

[1] Fletcher C.D., Berman J.J., Corless C. et al.: "Diagnosis of gastrointestinal stromal tumors: a consensus approach". Hum. Pathol., 2002, 33, 459.

[2] Miettinen M., Sobin L.H., Sarlomo-Rikala M.: "Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD! 17 (KIT)". Mod. Pathol., 2000, 13, 1134.

[3] Miettinen M., Lasota J.: "Gastrointestinal stromal tumors (GISTs): definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis". Virchows Arch., 2003, 438, 1.

[4] Miettinen M., Monihan J.M., Sarlomo-Rikala M., Kovatich A.J., Carr N.J., Emory T.S. et al.: "Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases". Am. J. Surg. Pathol., 1999, 23, 1109.

[5] Reith J.D., Goldblum J.R., Lyles R.H., Weiss S.W.: "Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome". Mod. Pathol., 2000, 13, 577.

[6] Miettinen M., Sarlomo-Rikala M., Sobin L.H. et al.: "Gastromtestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases". Am. J. Surg. Pathol., 2000, 24, 1339.

[7] Hirota S., Isozaki K., Moriyama Y. et al.: "Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors". Science, 1998, 279, 577.

[8] Rubin B.P., Singer S., Tsao C. et al.: "KIT activation is a ubiqmtous feature of gastrointestinal stromal tumors". Cancer Res., 2001, 61, 8118.

[9] Druker B.J., Talpaz M., Resta D.J. et al.: "Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia". N. Engl. J. Med., 2001, 344, 1031.

[10] Dagher R., Cohen M., Williams G. et al.: "Approval summary imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors". Clin. Cancer Res., 2002, 8, 3034.